⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21584978 | 0.89 | — | — | |
| SCHEMBL324340 | 0.89 | OTUD7B (0.46) | — | |
| SCHEMBL1429855 | 0.89 | OTUD7B (0.46) | — | |
| SCHEMBL3119994 | 0.89 | OTUD7B (0.46) | — | |
| SCHEMBL21584947 | 0.88 | OTUD7B (0.42) | — | |
| Hydrochloric Acid SCHEMBL325043 | 0.87 | OTUD7B (0.44) | — | |
| SCHEMBL4829 | 0.87 | OTUD7B (0.44) | — | |
| Hydrochloric Acid SCHEMBL2637685 | 0.87 | OTUD7B (0.44) | — | |
| Hydrochloric Acid SCHEMBL30159811 | 0.87 | OTUD7B (0.44) | — | |
| Hydrochloric Acid SCHEMBL7791830 | 0.85 | OTUD7B (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | claimed |
| WO-2024233544-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2024-11-14 | — | — | WO | claimed |
| CN-120476110-B | Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof | SHANGHAI HANSOH BIOMEDICAL Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4709723-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025202922-A1 | IMIDAZOPYRIDAZINE IL-17 INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-02 | — | — | WO | disclosed |
| US-20250270195-A1 | PD-1/PD-L1 INHIBITORS | GILEAD SCIENCES INC (US) | 2025-08-28 | — | — | US | disclosed |
| WO-2025149545-A1 | HETEROARYLPHENYL ETHER DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2025-07-17 | — | — | WO | disclosed |
| US-12338233-B2 | PD-1/Pd-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250179059-A1 | ANTICANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2025-06-05 | — | — | US | disclosed |
| WO-2025007915-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-09 | — | — | WO | disclosed |
| US-20180319771-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-11-08 | — | — | US | disclosed |
| US-20180265497-A1 | PYRIMIDINYL-PYRIDYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF TREATING IRE1-RELATED DISEASES AND DISORDERS | GENENTECH, INC. (US) | 2018-09-20 | — | — | US | disclosed |
| EP-3368524-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072021-A1 | HETEROARYLCARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-05-04 | — | — | WO | disclosed |
| WO-2016029839-A1 | (SUBSTITUTED PHENYL) (SUBSTITUTED PYRIMIDINE) AMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND MEDICATION USE | 四川海思科制药有限公司 | 2016-03-03 | — | — | WO | disclosed |
| WO-2014169845-A2 | 4,5-DIHYDRO-PYRAZOLO [3, 4-C] PYRID-2-ONES, PREPARATION METHOD AND APPLICATION THEREOF | 四川海思科制药有限公司 (CN) | 2014-10-23 | — | — | WO | disclosed |
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2411367-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109123-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |